Impact of hyperkalaemia on renin-angiotensin-aldosterone (RAAS) inhibitor reduction or withdrawal following hospitalisation.

MLA

Ellis, Hugh Logan, et al. “Impact of Hyperkalaemia on Renin-Angiotensin-Aldosterone (RAAS) Inhibitor Reduction or Withdrawal Following Hospitalisation.” Clinical and Experimental Medicine, vol. 25, no. 1, Dec. 2024, p. 16. EBSCOhost, https://doi.org/10.1007/s10238-024-01531-9.

APA

Ellis, H. L., Al-Agil, M., Kelly, P. A., Teo, J., Sharpe, C., & Whyte, M. B. (2024). Impact of hyperkalaemia on renin-angiotensin-aldosterone (RAAS) inhibitor reduction or withdrawal following hospitalisation. Clinical and Experimental Medicine, 25(1), 16. https://doi.org/10.1007/s10238-024-01531-9

Chicago

Ellis, Hugh Logan, Mohammad Al-Agil, Philip A Kelly, James Teo, Claire Sharpe, and Martin B Whyte. 2024. “Impact of Hyperkalaemia on Renin-Angiotensin-Aldosterone (RAAS) Inhibitor Reduction or Withdrawal Following Hospitalisation.” Clinical and Experimental Medicine 25 (1): 16. doi:10.1007/s10238-024-01531-9.